Episode 194: FDA's historic approval: How it affects your dental patients

Dental's pharmacology expert, Tom Viola, RPh, joins the show to talk about the U.S. Food and Drug Administration (FDA) approving dabigatran etexilate (Pradaxa) oral pellets for the treatment of venous thromboembolism (VTE) in children aged 3 months to less than 12 years. Viola discusses what dental practices need to know about this.